This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia.

Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. Phase 2 trial of an Alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia.  Schizophrenia Bulletin, June 12, 2015 [epub ahead of print].